Vitreous protein binding with nanopore dialysis membrane device

Area of Science:

• Ophthalmology
• Biomaterials Science
• Regenerative Medicine

Background:

• Age-related macular degeneration (AMD) is a leading cause of blindness, with no current therapies for the dry form.
• Existing treatments for wet AMD involve frequent intraocular injections, posing a significant treatment burden.
• There is a critical need for sustained, long-term therapeutic solutions for dry AMD.

Purpose of the Study:

• To develop and evaluate a novel implantable intraocular device for treating dry age-related macular degeneration (AMD).
• To assess the device's ability to adsorb and trap complement factors implicated in AMD pathogenesis.
• To determine the biocompatibility and efficacy of the implant in a preclinical model.

Main Methods:

• A novel implantable intraocular device utilizing a nanopore polyacrylonitrile polymer membrane was designed.
• The device was tested for its capacity to dialyze and absorb complement proteins from the vitreous.
• In vivo studies involved three-month implantation in New Zealand White Cross rabbits to assess biocompatibility and retinal health.

Main Results:

• Preliminary in vitro and in vivo studies showed the implant has high affinity and capacity for complement protein absorption.
• The three-month intraocular implantation in rabbits demonstrated excellent biocompatibility.
• No significant inflammation was observed, and normal retinal physiology and histology were maintained post-implantation.

Conclusions:

• A nanopore polymer membrane implant can effectively achieve prolonged intraocular complement factor suppression.
• This novel device presents a potential long-term therapeutic strategy for dry age-related macular degeneration.
• The implant's biocompatibility and efficacy suggest a promising new avenue for AMD treatment.